ABSTRACT Thirty-five patients (88% male) with pulmonary infection caused by Mycobacterium kansasii have been reviewed. Sixty-six per cent had pre-existing lung disease, chronic bronchitis and emphysema accounting for half of the disorders. Unilateral lesions were present in 69% of patients whose chest radiographs were reviewed and 90% had cavitating disease. The development of unilateral or bilateral disease appeared to be independent of any delay in starting treatment. Five patients died while receiving treatment, but none of these deaths was due to M kansasii infection. The remaining 30 patients were successfully treated with drug regimens, all of which included rifampicin and 86% of which included ethambutol. There was 100% sputum conversion, with no relapses after a mean follow-up period of five-and-a-half years. Rifampicin and ethambutol given for a mean period of 15 months appeared to be a non-toxic, effective combination.
Studies published in the last decade have shown the effectiveness of rifampicin in the treatment of pulmonary infection caused by the non-tuberculous mycobacterium M kansasii. 12 No uniform approach to treatment, however, has been established. Harris et al have recommended that until the rate of relapse is known in patients treated with and without regimens containing rifampicin this drug should be kept in reserve for patients requiring retreatment.' Others have recommended various combinations of rifampicin, ethambutol, isoniazid, and streptomycin.34 Some patients are treated with drug combinations which include cycloserine and ethionamide on the basis of in vitro sensitivity results. The aim of this retrospective study was to seek the simplest effective regimen which was well tolerated.
Methods
Cultures from all patients with non-tuberculous mycobacterial infection encountered in Wales are sent to the Mycobacterium Reference Unit in Cardiff for identification and sensitivity testing. From 1970 to 1979 50 patients were registered by the unit as having pulmonary infection due to M kansasii. Of 35 patients treated, five died while receiving treatment but none of these deaths was considered to be due to M kansasii infection (carcinoma of the rectum, disseminated prostatic carcinoma, massive haematemesis, and two cases of cor pulmonale). All five patients had become culture negative and had shown initial clinical improvement in response to treatment. As we were interested in the long-term follow-up of patients, they have not been included in the analysis of treatment regimens shown in tables 2 and 3.
The remaining 30 patients were all successfully treated with drug regimens containing rifampicin (tables 2 and 3). Ethambutol was included in all but four of the treatment regimens, and in nine patients this was given with rifampicin alone for 15 months on average.
All patients had satisfactory clinical responses with resolution of symptoms considered due to M kansasii. Continuing disability, when it occurred, was due to pre-existing chronic pulmonary disease. The sequential radiographs of 25 patients were reviewed. For the other five patients completing treatment chest radiographs were not available, but the radiographic reports in their case notes were reviewed. Radiographic evidence of healing of lesions with closure of cavities was observed in 24 Nine patients were treated with a combination of rifampicin and ethambutol given for an average of 15 months. This proved to be an effective, non-toxic combination. Rifampicin resistance has, however, developed in patients treated with this drug combined with ethambutol and isoniazid when in vitro sensitivity results have shown resistance to the two latter drugs.'0 Most patients in our study had organisms sensitive to ethambutol but in two there was borderline resistance. One of these two patients was successfully treated with a combination of rifampicin, viomycin, and isoniazid, and the other with rifampicin, cycloserine, and ethionamide. As a counsel of perfection we therefore suggest that cycloserine or ethionamide should be used as a third drug to complement rifampicin and ethambutol at the start of treatment until the results of ethambutol sensitivity tests are available.
